Drugs / Dextran
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT04970329 | Jul 2021 | dry eye syndrome | University of Faisalabad | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02863809 Background | Mar 2017 → Jun 2021 | keratinization disease | Joseph B. Ciolino, MD | Completed | No outcome recorded |
| Phase 1/2 | NCT02507362 Background | Aug 2014 → Dec 2015 | keratoconus | Tehran University of Medical Sciences | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dextran | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04970329 ↗ |
| Route | Topical | “riboflavin 0.1% combined with dextran 20 % will be instilled every 3 minutes” NCT02507362 ↗ |